Latest Financial Impact News

Great Divide Mining has transitioned its Challenger Gold Mine in NSW from commissioning to commercial production, targeting a gold concentrate grade of 30 grams per tonne from historic tailings with minimal capital expenditure.

Australian Clinical Labs has been hit with a class action lawsuit linked to a 2022 cyberattack on Medlab Pathology, alleging breaches of consumer law and duty of care. The company denies the claims and plans a vigorous defence.

Nuix has completed its acquisition of Paris-based Linkurious, integrating advanced graph data visualisation technology and boosting its full year Annualised Contract Value guidance to $252 million–$272 million.

Channel Infrastructure has locked in a government contract for 93 million litres of additional diesel storage at Marsden Point, adding about $8 million revenue in 2026 and reinforcing its role in New Zealand’s fuel security.

Fredon, NRW Holdings’ electrical and mechanical arm, has landed contracts worth around $160 million spanning major infrastructure, health, and electric vehicle projects across Australia, with work scheduled through to mid-2028.

Burgundy Diamond Mines has responded to ASX scrutiny over its related-party financing with Choron Holdings, asserting the arrangements were short-term, non-material cash-flow facilities properly disclosed in its half-year accounts.

Xenitra Limited’s Q3 sales soared to $8.3 million, a 300% jump over Q2, driven by its Nutritionals division and a strategic $30 million partnership with Rockcheck Group for Danone products. The company also launched new OTC medicines and blockchain tokenised sales channels poised to fuel future growth.

Fletcher Building posted a mixed quarterly volume update for Q3 FY26, with gains in light building products and distribution offset by weakness in heavy materials. The recent Middle East conflict adds new supply chain and cost pressures, complicating the outlook.

Love Group Global Ltd reported a 15% decline in quarterly customer cash receipts to $884k in Q3 FY26, driven by a sharp drop in Hong Kong. Despite this, the company maintained positive net operating cash flow and is pursuing growth in US and UK markets.

Cuscal Limited is set to acquire New Zealand payments provider Paymark for A$27 million, funded by a fully underwritten A$30 million institutional placement and a non-underwritten A$3 million share purchase plan. The deal, expected to complete by June 2026, will add scale and geographic diversification while being accretive to earnings in FY27.

Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.

Pro Medicus has secured a 5-year, A$37 million contract renewal with Northwestern Medicine, featuring higher minimum usage commitments and increased fees per transaction, reflecting growth in exam volumes.